XEDEV

What XEDEV does

XEDEV (Xedev BV) is a Belgian contract development and manufacturing organization (CDMO) specializing in solid dosage form drug product development for pharmaceutical and biotechnology clients. Founded in 2012 as a spin-off from sister company Procept's process equipment demo center, the company operates from a GMP-certified facility in Zele, Belgium, and serves clients from preclinical feasibility through Phase I and Phase II clinical manufacturing. Its core capabilities center on particle engineering technologies — primarily spray drying and hot melt extrusion — used to improve solubility and bioavailability of poorly soluble compounds, stabilize biologics and peptides, and produce amorphous solid dispersions (ASDs). Supporting services include granulation, tableting, bead coating, nano-suspensions, cyclodextrin complexation, and comprehensive analytical testing (XRPD, mDSC, FTIR, Raman, chromatography, ICH-compliant stability).

The company's technological differentiator is the integration of R&D and GMP laboratories using the same equipment, which eliminates or limits technology transfer when scaling from feasibility studies to clinical batches. Spray drying feasibility can begin at as little as 50 mg of solids, enabling data generation at very early development stages with minimal API consumption. The proprietary SD1L large-scale spray dryer, developed by sister company Procept, provides 5-6x greater capacity than the 4M8-TriX unit and supports modular scale-up via multiple drying columns in parallel. This equipment-and-formulation synergy with Procept constitutes a structural advantage that smaller standalone CDMOs cannot replicate.

XEDEV generates revenue through fee-for-service CDMO engagements on a project-by-project, quote-driven basis. Pricing is not publicly disclosed and depends on molecule complexity, service scope, batch sizes, and regulatory requirements. The go-to-market model is direct enterprise sales supported by a dedicated business development team and project managers, with demand generation occurring through major industry conferences (CPHI, BOS Basel, Festival of Biologics, PODD, Bio-Europe, AAPS PharmSci360) and the BIO-Europe partneringONE platform. The customer base spans primary pharmaceutical/biotech companies and secondary 'virtual pharma' ventures lacking internal manufacturing infrastructure, with active geographic engagement in EMEA, North America, and Asia (notably Japan via a 2025 FIT-organized trade mission). The company is privately held with no disclosed external funding rounds, operating with an 11-50 employee headcount.

Name

XEDEV

Legal name

Xedev BV

Website

https://xedev.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Xedev is a Belgian GMP-certified CDMO specializing in solid dosage form drug product development for pharmaceutical and biotech clients, with core capabilities in spray drying, hot melt extrusion, and particle engineering for poorly soluble compounds and biologics from preclinical through Phase II.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical CDMO services
• Drug product development
• Spray drying technology
• Hot melt extrusion
• GMP clinical manufacturing

Headquarters

HQ city

Zele

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Organization (CDMO) Services: Xedev generates revenue through fee-for-service CDMO engagements providing formulation development, process development, and GMP clinical batch manufacturing to pharmaceutical and biotech clients. Services are project-based and quote-driven, spanning from early preclinical feasibility through Phase I and II clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

XEDEV is a specialized pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering flexible formulation and manufacturing services for solid drug products. Its core activities are drug product development (solid dosage forms, solubility and bioavailability enhancement, analytical testing, and advanced solutions for biologics/peptides) and drug product manufacturing (preclinical R&D batches and GMP clinical batches for Phase I and II trials). The work is centered on enabling technologies such as spray drying and hot melt extrusion, supported by in-house analytical infrastructure and seamless R&D-to-GMP tech transfer.

Product overview

XEDEV is a Contract Development and Manufacturing Organization (CDMO) providing flexible formulation and manufacturing solutions for pharmaceutical drug product development. The company offers an integrated portfolio of services spanning Drug Product Development (including solid dosage forms, solubility enhancement via Amorphous Solid Dispersions, analytical testing, and advanced solutions for biologics/peptides) and Drug Product Manufacturing (preclinical, clinical Phase I/II, and scale-up services). Core technologies include Spray Drying and Hot Melt Extrusion for bioavailability enhancement, supported by particle engineering, granulation, tableting, and coating capabilities. The company operates both R&D and GMP facilities using the same equipment for seamless tech transfer, and shares its facility with sister company Procept for advanced processing equipment.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Product Development
• Drug Product Manufacturing
• Spray Drying Services
• Hot Melt Extrusion (HME) Services
• Amorphous Solid Dispersion (ASD) Formulation Services
• Solid Dosage Form Development
• Analytical Testing Services
• Clinical Manufacturing (Phase I & II)
• Preclinical Manufacturing
• Scale-up and Tech Transfer Services

Quantifiable outcome

• Spray drying capability starting at just 50 mg of solids (12.5 mg API at 25% drug load), enabling real solid-state data generation at early development stages with minimal material consumption
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered minor, flagship and core.

• FIT – Flanders Investment & TrademinorGTM or Marketing Partner · 1 June 2025Flanders Investment & Trade (FIT) organized the Life Sciences Week in Japan including business week activities in Tokyo and Osaka. Xedev participated in this economic mission alongside Flemish companies, universities, and research institutes. FIT facilitated F2F meetings, networking, and access to the Belgian pavilion at World Expo 2025.
• ProceptflagshipStrategic or Co-development PartnerProcept, founded in 1994, is Xedev's sister company and facility partner. Xedev was established from Procept's process equipment demo center in 2012. The two companies operate in a bi-directional strategic collaboration: Xedev integrates Procept's advanced technologies into its CDMO services, while Procept engineers provide immediate on-site technical support. This synergy combines pharmaceutical formulation expertise with advanced process equipment engineering, creating a unique integrated CDMO operation.
• Shin-EtsucoreTechnology or IntegrationShin-Etsu is a technology partner in the field of Amorphous Solid Dispersions. As part of the 5th Seminar on Amorphous Solid Dispersions, Shin-Etsu partners with Alexanderwerk, Frewitt, Procept, and Thermo Fisher Scientific to share latest insights into ASD development covering spray drying, hot melt extrusion, roller compaction, and milling. Xedev (through Procept) participates as a technology provider in this industry collaboration.
• Takanori MoriminorImplementation/ SI/ Consulting PartnerTakanori Mori provided day-to-day local support for Xedev during its business week activities in Japan (Tokyo and Osaka), serving as a local liaison and facilitator for business development activities in the Japanese market.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Hovione: Portugal-headquartered CDMO with deep, longstanding expertise in spray drying, amorphous solid dispersions, and particle engineering for solid oral dosage forms. Most directly comparable to Xedev on technology stack and customer profile (pharma/biotech formulation outsourcing).
• Recipharm: European-headquartered CDMO providing solid dose formulation, development, and clinical manufacturing services. Comparable to Xedev in serving pharma/biotech with Phase I/II clinical supply and solid-dosage expertise.
• Quotient Sciences: Integrated development and clinical manufacturing CDMO focused on accelerating molecules from formulation through Phase I/II clinical trials. Closely mirrors Xedev's integrated R&D-to-GMP, early-phase positioning for small molecules.
• Alcami: US-based CDMO offering formulation development, analytical services, and GMP clinical manufacturing for solid and other dosage forms. Comparable mid-sized peer competing for similar early-phase pharma/biotech outsourcing work.
• Eurofins CDMO: Eurofins' contract development and manufacturing arm provides formulation, analytical, and GMP services for pharma/biotech. Overlaps with Xedev in European clinical-stage solid-dose formulation work.

Broad incumbents

• Catalent: Large global CDMO offering formulation, clinical and commercial manufacturing for solid dose forms including spray-dried ASDs. Competes with Xedev for early-stage solid-formulation work but offers a much broader service portfolio and global site network.
• Lonza: Global CDMO with small-molecule and biologics drug-product capabilities including spray-dried intermediates. Overlaps with Xedev in solid-dose formulation and ASD development but at vastly greater scale and service breadth.
• Cambrex: CDMO with small-molecule API and drug product capabilities including solid-dose development. Competes in adjacent formulation/CDMO space but typically at larger scale and broader scope than Xedev.
• Patheon (Thermo Fisher Scientific): Part of Thermo Fisher's pharma services, offering global formulation development and clinical/commercial manufacturing. Overlaps with Xedev on solid-dose formulation and GMP Phase I/II supply but at vastly broader scale.

Regional players

• Hermes Pharma: European CDMO specializing in oral solid dosage forms including user-friendly dosage forms for patient-centric drug delivery. Comparable scale and service focus but with distinct niche (patient-centric oral forms) versus Xedev's enabling-formulation focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/xedev

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XEDEV